Topic archive
MedTech Current publications and recall entries tagged Surgical, Interventional & Implantable Devices.
FDA's updated provider letter lists five models under an October 20, 2026 heading, while preserving qualified use of existing equipment and exclusions for related supplies. Import restrictions remain product- and facility-specific.
The labeled diameter guides implant selection in a neurovascular procedure. A small reported quantity does not remove the concern: the implant remains permanently in the patient. The response therefore covers unused stock and patients already treated, whose records need review to assess whether follow-up is appropriate.
The positioner supports the patient’s upper body and head during surgery; a failed joint can disrupt positioning. Facilities must locate and check affected devices. Continued use depends on passing the safety check. Passing devices still need exchange for an upgraded unit.
A reproduced CMDE neurostimulator draft details MRI configuration coverage, battery management and remote-programming evidence. Field strength alone does not justify test coverage, and battery evidence includes the interval from warning to loss of power. The copy remains unauthenticated against the official original.
An interruption during breast biopsy may delay sampling or require a repeat procedure. Facilities need a workable fallback for affected systems and access for the planned software update, with clinicians informed before the next use.
Holes in the package may compromise sterility before an invasive embolization procedure. Interventional facilities need to locate the affected syringes, stop using them, and trace any stock supplied to other sites.
Potential monomer leakage changes how staff handle these pre-filled cement systems. The notice calls for eye protection during operation and an immediate stop if leakage appears; the all-lot scope across four configurations also broadens inventory checks.
FDA classified Boston Scientific's Imager II Angiographic Catheter recall as Class I after reduced stabilizing agents in catheter tips were linked to tip degradation and possible detachment during use.
NMPA has opened comment on revised GMP inspection guides for sterile and implantable medical devices. The drafts combine the revised general GMP with the relevant special appendices and classify findings as critical, major, or general; comments are due October 8, 2026.
FDA has issued draft recommendations for premarket submissions covering certain robotically-assisted surgical devices, including device description, non-clinical testing, software, cybersecurity, human factors, clinical data, and labeling. The draft is not for implementation, and comments are due November 24, 2026.
FDA classified Abiomed's Automated Impella Controller removal as Class I after purge-flag failures caused purge-cassette recognition problems that can delay support or require controller exchange during active support.
The affected products are implanted orthopaedic components, and the FDA record links increased material oxidation to wear-related outcomes that may include pain, inflammation, and revision surgery. For manufacturers, the event also illustrates how raw-material aging controls and process-change governance can propagate across numerous implant configurations and product families.
Unintended motion during orthopedic robotic procedures has obvious procedural implications and creates a high-priority field response despite the relatively small installed base. The event also distinguishes the recalled robotic-assist component from related navigation and camera equipment that the official notice permits facilities to continue using.
FDA has classified the recall of Boston Scientific Infinion CX Leads as Class I. The manufacturer is removing unused leads due to mechanical stress at anchor sites that may cause lead fractures and inadequate stimulation.
Unintended movement of an operating table during a procedure creates a direct procedural safety concern even though the affected installed base is small. The recall is also operationally significant because facilities must perform interim daily checks and locked-position verification until field service replaces the affected components with an updated design.
A machining nonconformance in an implant component can become consequential at the point of surgery, where proper screw engagement is part of fixation. The response also requires removal of affected unused product from implant sets and consignment inventory, making traceability and inventory control important beyond the manufacturing site.
FDA has classified the recall of specified BD Intraosseous Vascular Access System Needle Set lots as Class I after out-of-tolerance dimensions were linked to difficulty removing the obturator and potential delays in therapy; the FDA recall database lists Bard Access Systems, Inc. as the recalling firm.
The event combines a physical device-design hazard with a software field correction, making it relevant to both hardware and software quality teams. Its nationwide scope and representative-installed software also create operational work for facilities while the FDA record permits continued use under existing warnings and instructions until correction.
An incorrect component inside a procedure kit can create a mismatch at the point of use even when the outer product identity appears correct. The event is relevant to vascular-device manufacturers and hospitals because it illustrates the importance of kit-component verification, inventory isolation, and downstream traceability for distributed procedural products.